Wedbush Lifts Earnings Estimates for Viridian Therapeutics

Key Points

• Wedbush raised its Q3 2025 EPS estimate for Viridian Therapeutics from ($0.78) to ($0.13), reflecting improved earnings expectations.
• Viridian's current full-year earnings consensus estimate stands at ($4.03) per share, with projections indicating declining losses through FY2026.
• Several analysts issued adjusted price targets for Viridian Therapeutics, with Oppenheimer increasing theirs from $28.00 to $32.00 and Goldman Sachs raising theirs from $27.00 to $30.00.

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Analysts at Wedbush boosted their Q3 2025 earnings per share estimates for shares of Viridian Therapeutics in a research note issued on Wednesday, August 6th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.13) per share for the quarter, up from their prior estimate of ($0.78). The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share. Wedbush also issued estimates for Viridian Therapeutics' Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($2.83) EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.88) EPS, Q3 2026 earnings at ($0.87) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($3.27) EPS, FY2027 earnings at ($1.07) EPS and FY2029 earnings at $7.23 EPS.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($1.00) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.00). The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%. Viridian Therapeutics's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.81) EPS.

Other equities research analysts have also issued research reports about the company. HC Wainwright restated a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. The Goldman Sachs Group upped their price target on Viridian Therapeutics from $27.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, August 7th. Needham & Company LLC reduced their price target on Viridian Therapeutics from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. JMP Securities reduced their price target on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, Oppenheimer upped their price target on Viridian Therapeutics from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $37.00.

Viridian Therapeutics Price Performance

VRDN stock traded down $0.61 during midday trading on Monday, reaching $18.24. 97,898 shares of the stock were exchanged, compared to its average volume of 893,792. The stock has a market capitalization of $1.49 billion, a PE ratio of -4.79 and a beta of 0.42. Viridian Therapeutics has a 52 week low of $9.90 and a 52 week high of $27.20. The company has a debt-to-equity ratio of 0.04, a current ratio of 11.01 and a quick ratio of 11.01. The company has a fifty day moving average price of $16.17 and a 200 day moving average price of $15.20.

Hedge Funds Weigh In On Viridian Therapeutics

Several large investors have recently bought and sold shares of VRDN. Amalgamated Bank increased its position in shares of Viridian Therapeutics by 49.7% during the first quarter. Amalgamated Bank now owns 2,531 shares of the company's stock valued at $34,000 after acquiring an additional 840 shares during the last quarter. Foresite Capital Management VI LLC purchased a new stake in shares of Viridian Therapeutics during the fourth quarter valued at approximately $38,000. GAMMA Investing LLC increased its position in shares of Viridian Therapeutics by 3,892.9% during the first quarter. GAMMA Investing LLC now owns 8,425 shares of the company's stock valued at $114,000 after acquiring an additional 8,214 shares during the last quarter. Summit Investment Advisors Inc. increased its position in shares of Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after acquiring an additional 1,516 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Viridian Therapeutics during the second quarter valued at approximately $170,000.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.